1039例隐源性肝炎患者AMA-M2 抗体的筛查

doi:10.3969/j.issn.1672-5069.2012.03.021

实用肝脏病杂志 ›› 2012, Vol. 15 ›› Issue (3): 238-240.doi: 10.3969/j.issn.1672-5069.2012.03.021

1039例隐源性肝炎患者AMA-M2 抗体的筛查

张玮, 王磊, 王奕, 王俐琼, 杜慧慧, 李青梅

200032 上海市上海中医药大学附属龙华医院

收稿日期:2011-08-02 出版日期:2016-06-10 发布日期:2016-05-11
作者简介:张玮女,46岁,主任医师,硕士研究生导师。主要从事中西医结合治疗肝病的临床研究。E-mail:ww44doctor@yahoo.com.cn

Measurement of anti-mitochondria M₂ antibodies in 1039 patients with cryptogenic hepatitis

Zhang Wei, Wang Lei, Wang Yi, et al.

Longhua Hospital,University of Chinese Traditional Medicine,Shanghai 200032

Received:2011-08-02 Online:2016-06-10 Published:2016-05-11

摘要/Abstract

摘要： 目的在1039例隐源性肝炎患者中筛查AMA-M₂抗体,对男性和女性的M₂抗体滴度、M₂抗体阳性患者和M₂抗体阴性患者的免疫指标、PBC患者的临床表现等进行统计分析,以早期诊断PBC。方法采用ELISA法检测M₂抗体滴度。结果在1039例隐源性肝炎患者中,81例（7.9%）M₂抗体阳性,其中57例为女性,24例为男性,平均年龄53.0±14.8岁;在78例PBC患者中,乏力（74.4%,58/78）、黄疸（61.5%,48/78）和皮肤瘙痒（37.2%,29/78）多见;合并ANA阳性者39例（50.0%,39/78）,合并抗-SSA/Ro抗体阳性14例（17.9%,14/78）。结论AMAs的检测是诊断原发性胆汁性肝硬化的重要指标,检测M₂抗体有助于早期诊断PBC。

关键词: 隐源性肝炎, 原发性胆汁性肝硬化, AMA-M2抗体

Abstract: Objective To investigate the presence of AMA-M₂ antibodies in 1039 patients with cryptogenic hepatitis. Methods M₂ antibodies were tested by ELISA. Results M₂ antibodies were detected in 81（7.9%）of the 1039 patients;Of the 81 cases,57 were female and 24 were male,and the mean age was 53.0 ± 14.8 year old,and 78 patients were diagnosed as PBC;The most common symptoms were fatigue（74.4%,58/78）,jaundice（61.5%,48/78）and skin itching（37.2%,29/78）;Besides,39（50.0%） patients were with ANA positive,and 14（18.0%） with anti-SSA/Ro positive. Conclusion On the diagnosis of the disease,the detection of serum antimitochondrial autoantibodies（AMA） is an important indicator. The detection of AMA-M₂ is important for early diagnosis of patients with PBC.

Key words: Cryptogenic hepatitis, Primary biliary cirrhosis, Anti-mitochondria M2 antibodies

张玮, 王磊, 王奕, 王俐琼, 杜慧慧, 李青梅. 1039例隐源性肝炎患者AMA-M2 抗体的筛查[J]. 实用肝脏病杂志, 2012, 15(3): 238-240.

Zhang Wei, Wang Lei, Wang Yi, et al.. Measurement of anti-mitochondria M₂ antibodies in 1039 patients with cryptogenic hepatitis[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2012, 15(3): 238-240.

参考文献

[1] Lleo A,Battezzati PM,Selmi C,et al. Is autoimmunity a matter of sex?. Autoimmun Rev,2008,7:626-630.
[2] Roblin X,Bonaz B.Primary biliary cirrhosos. N Engl J Med,2005;353:2719-2720.
[3] Prince MI,Chetwynd A,Craig WL,et al. Asymptomatic primary biliary cirrhosis:clinical features,prognosis,and symptom progression in a large population based cohort. Gut,2004,53:865-870.
[4] Selmi C,Bowlus C,Gershwin ME,et al. Primary biliary cirrhosis. Lancet,2011,377:1600-1609.
[5] Invernizzi P. Update on primary biliary cirrhosis. Digest Liver Dis,2010,42:401-408.
[7] Muratori P,Granito A,Pappas G,et al. The serological profile of the autoimmune hepatitis/primary biliary cirrhosis overlap syndrome. Am J Gastroenterol,2009,104（6）:1420-1425.
[8] 蒋天舒,周晔,邓安梅,等. 原发性胆汁性肝硬化研究进展. 中国实验诊断学,2006,10（12）：1539-1541.
[9] Gershwin ME,Mackay IR. The causes of primary biliary cirrhosis:convenient and inconvenient truths. Hepatology,2008,47:737-745.
[10] Shimoda S,Miyakawa H,Nakamura M,et al. CD4 T-cell autoreactivity to the mitochondrial autoantigen PDC-E2 in AMA-negative primary biliary cirrhosis. J Autoimmun,2008,31:110-115.
[11] Shimoda S,Harada K,Niiro H,et al. Biliary epithelial cells and primary biliary cirrhosis:the role of liver-infiltrating mononuclear cells. Hepatology,2008,47:958-965.
[12] Murator I,Granito A,Ferri S,et al.Multiple nuclear dots and rim-like/membranous IgG isotypes in primary biliary cirrhosis .Autoimmunity,2009,42:224-227.
[13] Agmon-levin N,Shapira Y,Selmi C,et al. A comprehensive evaluation of serum autoantibodies in primary biliary cirrhosis. J Autoimmun,2010,34:55-58.
[14] Invernizzi P,Lleo A,Podda M. Interpreting serological tests in diagnosing autoimmune liver disease. Semin Liver Dis, 2007,27:161-172.
[15] Vleggaar FP,Van Buuren HR. No prognostic signif icance of antim-itochondrial antibody profile testing in primary biliary cirrhos-is. Hepatogastroenterology,2004,51（58）:937-940.
[16] Metcalf JV,Mitchison HC,Palmer JM,et al. Natural history of early primay biliary cirrhosis. Lancet,1996,348:1399-1402.
[17] Muratori P,Muratori L,Ferrari R,et al. Characterization and clinical impact of antinuclear antibodies in primary biliary cirrhosis. Am J Gastroenterol,2003,98:431-437.
[18] Zhang W,Yang GX. Fine phenotypic and functional characterization of effector CD8（+） T cells in patients with primary biliary cirrhosis. Hepatology,2011,[Epub ahead of print]
[19] Hsu W,Zhang W,Tsuneyama K,et al. Differential mechanisms in the pathogenesis of autoimmune cholangitis versus inflammatory bowel disease in interleukin-2Ralpha（-/-）mice.Hepatology,2009,49:133-140.
（校对：陈从新）

[1]	陈梅梅, 段晓燕, 曹海霞, 丁雯瑾. 复方鳖甲软肝片治疗原发性胆汁性肝硬化患者疗效分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 880-883.
[2]	郭晓霞, 郭琲婷, 孔祥璐. 脾切除对原发性胆汁性肝硬化小鼠肝组织纤维化影响研究^*[J]. 实用肝脏病杂志, 2018, 21(6): 837-841.
[3]	刘映川, 赵鹏程, 游亭, 邓红英, 薛江凤. 熊去氧胆酸联合维生素D治疗PBC患者疗效和外周血T淋巴细胞亚群的变化[J]. 实用肝脏病杂志, 2018, 21(6): 907-910.
[4]	刘进国, 王暴魁. 复方鳖甲软肝片联合丁二磺酸腺苷蛋氨酸和熊去氧胆酸治疗PBC患者疗效及其对血清肝纤维化指标的影响*[J]. 实用肝脏病杂志, 2018, 21(3): 340-343.
[5]	秦维, 陈宇萍, 杨昭, 祝素平, 霍玉玲, 李木松. 原发性胆汁性肝硬化患者肝组织转化生长因子β-1表达水平变化[J]. 实用肝脏病杂志, 2018, 21(2): 237-240.
[6]	陈小君, 宋洋. UDCA联合维生素D治疗原发性胆汁性肝硬化患者外周血T细胞亚群变化及其对疗效的影响[J]. 实用肝脏病杂志, 2018, 21(1): 80-83.
[7]	陶明玲, 张世斌, 吴燕京, 郭晓红, 丁惠国. 原发性胆汁性肝硬化患者食管静脉曲张特点及其无创预测指标研究^*[J]. 实用肝脏病杂志, 2017, 20(4): 439-442.
[8]	刘复娜, 刘江奎, 沈毅慧. 泼尼松龙联合熊去氧胆酸治疗原发性胆汁性肝硬化患者疗效初步研究[J]. 实用肝脏病杂志, 2017, 20(4): 443-446.
[9]	郭锐, 覃进. 随机对照试验研究熊去氧胆酸治疗原发性胆汁性肝硬化患者的疗效及安全性^*[J]. 实用肝脏病杂志, 2017, 20(1): 109-110.
[10]	韩永斌，刘欣，王爱芳，周强，郭亚平. 原发性胆汁性肝硬化被误诊为骨髓增生异常综合征1例[J]. 实用肝脏病杂志, 2016, 19(6): 747-748.
[11]	郝建宏,郝海燕,胡忆玲. 94例原发性胆汁性肝硬化临床特征分析[J]. 实用肝脏病杂志, 2016, 19(3): 352-353.
[12]	周新人, 王方, 云升皓, 寇俊峰, 蔡国芳, 杨兴坤, 冯淑贤. 脐带血干细胞治疗失代偿期原发性胆汁性肝硬化疗效观察[J]. 实用肝脏病杂志, 2016, 19(2): 219-220.
[13]	王眭，王江滨. 老年原发性胆汁性肝硬化患者的特点[J]. 实用肝脏病杂志, 2015, 18(6): 573-574.
[14]	孔祥璐，郭晓霞. 中药联合熊去氧胆酸胶囊治疗原发性胆汁性肝硬化疗效系统评价^*[J]. 实用肝脏病杂志, 2015, 18(4): 379-382.
[15]	李萍英，陆伦根. 原发性胆汁性肝硬化药物治疗进展[J]. 实用肝脏病杂志, 2015, 18(4): 441-444.

1039例隐源性肝炎患者AMA-M2 抗体的筛查

Measurement of anti-mitochondria M₂ antibodies in 1039 patients with cryptogenic hepatitis

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

1039例隐源性肝炎患者AMA-M2 抗体的筛查

Measurement of anti-mitochondria M2 antibodies in 1039 patients with cryptogenic hepatitis

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

Measurement of anti-mitochondria M₂ antibodies in 1039 patients with cryptogenic hepatitis